Je ten istý tyrozín- kinázový inhibítor efektívny aj po vzniku mozgových metastáz? Kazuistika
[Is the same tyrosine kinase inhibitor still effective after development of brain metastases? A Case report]
Language Czech Country Czech Republic Media print
Document type Case Reports, Journal Article
PubMed
23961860
DOI
10.14735/amko2013286
PII: 41260
- MeSH
- Indoles MeSH
- Enzyme Inhibitors therapeutic use MeSH
- Carcinoma, Renal Cell drug therapy MeSH
- Humans MeSH
- Kidney Neoplasms drug therapy MeSH
- Brain Neoplasms drug therapy secondary MeSH
- Disease Progression MeSH
- Antineoplastic Agents therapeutic use MeSH
- Pyrroles MeSH
- Aged MeSH
- Sirolimus MeSH
- Sunitinib MeSH
- TOR Serine-Threonine Kinases metabolism MeSH
- Protein-Tyrosine Kinases antagonists & inhibitors MeSH
- Treatment Outcome MeSH
- Check Tag
- Humans MeSH
- Male MeSH
- Aged MeSH
- Publication type
- Journal Article MeSH
- Case Reports MeSH
- Names of Substances
- Indoles MeSH
- Enzyme Inhibitors MeSH
- Antineoplastic Agents MeSH
- Pyrroles MeSH
- Sirolimus MeSH
- Sunitinib MeSH
- TOR Serine-Threonine Kinases MeSH
- Protein-Tyrosine Kinases MeSH
There is a new era of treatment options since introduction of new biological targeted therapies (tyrosine kinase inhibitors (TKIs) and mammalian target of rapamycin (mTOR) inhibitors) in renal cell cancer. However, in patients who developed brain metastases, there is still treatment dilemma about an optimal therapeutic scenario, particularly in the subgroup of patients with-out disease progression outside the central nervous system. The objective of this case report is to present that it is possible to continue the same targeted therapy after development of brain metastasis after application of local whole brain irradiation with meaningful overall survival.
References provided by Crossref.org
